Last reviewed · How we verify
Luveris (r-hLH)
Luveris (r-hLH) is a recombinant human luteinizing hormone (r-hLH) gonadotropin developed by EMD SERONO. It targets the lutropin-choriogonadotropic hormone receptor and is used to treat indications such as assisted reproduction. Luveris is a small molecule drug, FDA-approved in 2004, and its commercial status is patented. Key safety considerations include potential allergic reactions and the risk of ovarian hyperstimulation syndrome. It is essential to follow the recommended dosing and monitoring guidelines to minimize these risks.
At a glance
| Generic name | r-hLH |
|---|---|
| Also known as | LHadi®, Lutropin alfa; Luveris® |
| Sponsor | Merck KGaA |
| Drug class | Gonadotropin |
| Target | Lutropin-choriogonadotropic hormone receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2004 |
Approved indications
Common side effects
Key clinical trials
- An Ethno-bridging Study of Pergoveris in Healthy Premenopausal Participants of Japanese or Caucasian Origin (PHASE1)
- A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH and FSH Deficiency Undergoing ART (HINATA) (PHASE3)
- Aurora Test for Patients Treated With Recombinant Gonadotropins
- Potential Benefit of r-hLH Addition in Patients Aged 35 to 40 Under Ovarian Stimulation Treatment (PHASE4)
- Ruxolitinib as First Line Treatment in Primary Haemophagocytic Lymphohistiocytosis (R-HLH) (PHASE2)
- GTP Regimen in the Treatment of Refractory/Recurrent HLH (PHASE3)
- Pergoveris FD and Liquid China BE Study (PHASE1)
- Treosulfan and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Nonmalignant Inherited Disorders (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Luveris CI brief — competitive landscape report
- Luveris updates RSS · CI watch RSS
- Merck KGaA portfolio CI